



Use of Adjuvant Intravenous Bevacizumab for Aggressive Recurrent Respiratory Papillomatosis - A Case Report

Deepa Shivnani^{1*}, EV Raman¹, Shruthi Kobal¹, Sathwika¹ and Poonam Patil²

¹Children's Airway and Swallowing Center, Department of Otolaryngology and Head and Neck Surgery, Manipal Hospitals, Bangalore, India

²Department of Radiation Oncology, Manipal Hospitals, Bangalore, India

***Corresponding Author:** Deepa Shivnani, Children's Airway and Swallowing Center, Department of Otolaryngology and Head and Neck Surgery, Manipal Hospitals, Bangalore, India.

Received: July 13, 2023

Published: September 06, 2023

© All rights are reserved by **Deepa Shivnani, et al.**

Abstract

Recurrent Respiratory Papillomatosis (RRP) is a benign condition which needs frequent surgical interventions for debulking of papillomatosis lesions for securing the airway. There is no definitive treatment for the management of RRP so far. Bevacizumab either intralesional or systemic has emerged as a promising solution for RRP patients undergoing repeated surgeries. We are reporting a case of a 6-year-old child with juvenile onset RRP who was treated by surgical excision of lesion with adjuvant systemic bevacizumab therapy.

Keyword: Recurrent Respiratory Papillomatosis; JORRP; Medical Treatment; Bevacizumab

Introduction

Recurrent Respiratory Papillomatosis (RRP) is caused by Human Papilloma Virus and characterised by recurrent papilloma of respiratory tract mainly involving the larynx. The symptoms can vary from the hoarseness to the acute airway obstruction due to extensive papillomatous lesion. Two forms have been characterised – JoRRP – Juvenile onset which presents below the age of 12 years and Adult onset - AoRRP which is Adult age group. In a Juvenile form, transmission of HPV is believed to occur from the mother to the foetus during the vaginal delivery.

In JoRRP, child may become symptomatic between the age 2 to 6 years. The initial presenting symptoms could be dysphonia, progressive stridor, respiratory distress or sometimes with

recurrent cough and haemoptysis. In developing country like India patients are often misdiagnosed due to the lack of healthcare facilities in general and ENT services in particular. Flexible laryngoscopic examination and biopsy are mandatory to confirm the diagnosis. Surgical debulking of the lesion to maintain the airway patency is the mainstay of treatment [1]. The recurrent nature of the disease can be devastating in a young child. Various systemic and intralesional adjuvant therapies have been proposed in literature but very limited data is available for paediatric age group. The purpose of this case report is to share our experience in an aggressive juvenile RRP case who was successfully treated with multiple surgical procedures and intravenous bevacizumab therapy.

Case Report

A 6-year old girl from lower socioeconomic background was first presented in 2017 as an out-patient with a history of hoarseness of voice for 3 months. She had been treated for gastro esophageal reflux disorder empirically with no improvement in symptoms. She underwent direct laryngoscopic examination and extensive lesion noticed at the larynx obscuring the airway completely (Image 1).




Image 1: Laryngeal papilloma lesion involving bilateral false vocal cords causing 90 % obstruction in the airway lumen.

The lesion was removed with the help of microdebrider. Initially, child underwent multiple debulking procedures every 3–4 weeks interval since 2018 when the papillomas were limited only on laryngeal surface. Later, the child underwent tracheostomy due to excessive respiratory distress in 2019 during which the symptoms increased and the lesions became more extensive (Image 2) and obvious at the level of trachea and carina.



Image 2: Extensive papillomatosis lesion causing complete obstruction of airway.

She underwent overall 64 procedures before starting the intravenous bevacizumab therapy. Intravenous bevacizumab (Avastin, Genetech Inc.) was started with the dose of 10 mg/kg body weight infusion every 3 weekly when the patient’s airway status deteriorated. The family counselling was done about the risks of bevacizumab and its off-label use for this indication. The patient was monitored with blood pressure testing on the days of the procedures/infusions. Prior to each infusion, lab work was sent for a complete metabolic profile, urine protein: creatinine ratio, magnesium, and phosphorous. Remarkable improvement was noticed in her laryngotracheal disease within 9 weeks of therapy. The patient had significantly lower disease burden at the laryngeal level and in the trachea (Image 3).




Image 3a and 3b

3a- reduction in laryngeal lesion after first dose of intravenous bevacizumab.

3b- remarkable reduction in the papilloma lesion after 3 doses of intravenous bevacizumab.

She is still on follow up and the interval between the procedures have been prolonged to 6-8 months. The patient had no major or minor complication from the chemotherapy to date.

Discussion

RRP can be life threatening as it can cause airway narrowing due to mass effect of the papillomatous lesion. The most common outcome is mortality related to difficult intubation/anaesthesia, cancerous transformation and severe pulmonary infections. The classical treatment modality is surgical debridement. The adjuvant therapies are advocated in cases with multiple surgical procedures, extensive lesions and in the cases with pulmonary involvement [2].

Bevacizumab (Avastin, Genetech Inc., South San Francisco, CA) is a recombinant humanized monoclonal immunoglobulin

G antibody which inhibits angiogenesis of the human vascular endothelial growth factor-A (VEGF) and blocking their binding to VEGF receptors (VEGFR). Bevacizumab blocks the development of a tumor's own blood supply and helps slow down the tumour growth [3]. Intralesional or Intravenous administration of bevacizumab have shown beneficial effect in increasing the interval between surgeries as well as resolution of the lesions in a few patients. The improvement in voice outcome has been noticed too [4,5].

While intralesional injections are not reported to have any systemic complications, systemic administration of the drug is known to cause fewer side effects like proteinuria, hypertension, joint pain, haemoptysis, and lethargy which mostly improve after discontinuation of therapy and had been reported more in adults than children [6-8].

Conclusion

The mainstay of treatment is surgical excision of papillomatosis lesion. Adjuvant therapy with intravenous bevacizumab has shown promising results and can be used in aggressive RRP cases. Although bevacizumab usage has been increased in recent past for the management of RRP, its efficacy for intralesional and systemic administration needs multicentric trials. The long term side effects and dose adjustments need further research for paediatric cases.

Declaration

Informed consent for publication was taken from the parents of the child.

Financial Disclosure

The authors have no funding, financial relationships or conflicts of interest to disclose.

Bibliography

1. Carifi M., *et al.* "Recurrent respiratory papillomatosis: current and future perspectives". *Therapeutics and Clinical Risk Management* 11 (2015): 731-738.
2. Schraff S., *et al.* "American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy". *Archives of Otolaryngology--Head and Neck Surgery* 130.9 (2004): 1039-1042.
3. Best SR., *et al.* "Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey". *Laryngoscope* 127.10 (2017): 2225-2229.
4. Bedoya A., *et al.* "Systemic bevacizumab for recurrent respiratory papillomatosis: a single centre experience of two cases". *American Journal of Case Reports* 18 (2017): 842-846.
5. Rahbar R., *et al.* "Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis". *Annals of Otolaryngology, Rhinology, and Laryngology* 114.4 (2005): 289-295.
6. Mohr M., *et al.* "Rapid response to systemic Bevacizumab therapy in recurrent respiratory papillomatosis". *Oncology Letter* 8 (2014): 1912-1918.
7. Taugourdeau-Raymond S., *et al.* "Bevacizumab induced serious side-effects: a review of the French pharmacovigilance database". *European Journal of Clinical Pharmacology* 68 (2012): 1103-1107.
8. De Pasquale MD., *et al.* "Bevacizumab in pediatric patients: how safe is it?" *Anticancer Research* 31 (2011): 3953-3957.